跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00063388
NCT00063388已完成2 期

A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company9 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2003年5月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
66
试验地点
9
主要终点
The primary objective of this study was to determine the tumor response rate for single-agent cetuximab in EGFR+ subjects.
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Determine tumor response rate and time to disease progression, survival and safety in total populations.

详细描述

To determine the tumor response rate and time to disease progression, survival and safety in the EGFR-positive, EGFR-negative and total populations.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The primary objective of this study was to determine the tumor response rate for single-agent cetuximab in EGFR+ subjects.

时间窗: Every 8 weeks

次要结局

  • Determine the tumor response rate in the total population and in EGFR- subjects(Every 8 weeks)
  • Time to disease progression in the EGFR+ and total populations.(Every 8 weeks)
  • Survival in the EGFR+ and total populations.(Every 8 weeks)
  • Safety in the EGFR+ and total populations.(Every 8 weeks)

研究者

申办方类型
Industry

研究点 (9)

Loading locations...

相似试验

已完成
2 期
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)Cancer of Head and Neck
NCT00343083University of Maryland, Baltimore43
已完成
2 期
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)Squamous Cell Carcinoma of the Head and Neck
NCT00971932Merck KGaA, Darmstadt, Germany33
终止
2 期
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal CarcinomaOvarian Cancer
NCT00082212Eli Lilly and Company25
已完成
2 期
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube CancerPeritoneal NeoplasmsFallopian Tube NeoplasmsOvarian Cancer
NCT00063401Eli Lilly and Company39
终止
2 期
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior TherapyNon-small Cell Lung Cancer
NCT00694603Lecia V. Sequist56